MICO: Role of Microparticles in Covid-19 Infection

Sponsor

University Hospital, Strasbourg, France (Other)

Overall Status

Completed

CT.gov ID

NCT04448743

Collaborator

(none)

189

Enrollment

Location

15.1

Actual Duration (Months)

12.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Among the distinctive features of Covid-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset. Microparticles (MPs) shed by apoptotic/stimulated cells are reliable markers of vascular damage released upon pro-inflammatory conditions and behave as active participants in the early steps of clot formation. In addition, MPs carry ACE1 and ACE2, the cell-entry receptor for SARS-Cov2 in the vasculature and up-regulate ACE1 expression in neighbouring endothelial cells. This may contribute to unopposed angiotensin II accumulation which further exacerbate tissue injury and promote both inflammation and thrombosis. The aim of the study is to evaluate the impact of circulating MPs on ACE2 expression, the cell-entry receptor for SARS-Cov2 on endothelial cells.

Condition or Disease	Intervention/Treatment	Phase
COVID-19	Other: Blood sample

Detailed Description

Circulating MPs will be isolated from Covid-19 patients with lupus anticoagulant, from coronary artery diseases patients and from healthy volunteers without cardiovascular risk factors. Quantification of MPs will be realized by prothrombinase assay. Primary endothelial cells (ECs) from porcine coronary artery or porcine pulmonary artery will be isolated and cultured. ECs will be exposed to circulating MPs. Phenotypical changes (ACE2 expression, cytoadhesins, cytokines, tissue factor expression) of ECs will be examined. Susceptibility of ECs to SARS-COV-2 infection will be determined.

Study Design

Study Type:

Observational

Actual Enrollment :

189 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Role of Circulating Microparticles in Covid-19 Infection

Actual Study Start Date :

Jul 2, 2020

Actual Primary Completion Date :

Oct 4, 2021

Actual Study Completion Date :

Oct 4, 2021

Arms and Interventions

Arm	Intervention/Treatment
Covid-19 patients	Other: Blood sample 20 Ml blood sample
patients with coronary artery disease	Other: Blood sample 20 Ml blood sample
healthy volunteers	Other: Blood sample 20 Ml blood sample

Arm

Intervention/Treatment

Covid-19 patients

Other: Blood sample

20 Ml blood sample

patients with coronary artery disease

Other: Blood sample

20 Ml blood sample

healthy volunteers

Other: Blood sample

20 Ml blood sample

Outcome Measures

Primary Outcome Measures

Western blot measurement of ACE2 receptor expression in porcine cells [Through study completion, an average of 1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

COVID-19 patients: age > 18 yr
SARS-COV-2 infection within 12 months and positive lupus anticoagulant
Patients with cardiovascular risk factors: at least among
Hypertension, Dyslipidemia, Diabetes mellitus, obesity, smoker, Healthy volunteers